Abstract: A clamping device configured to secure a strap to a rail of a support table or operating table is provided, which prevents the patient from slipping, provides optimal patient stability when the table is placed in angle positions, and eliminates patient re-positioning during surgical procedure. The clamping device includes a body portion having a plurality of rail arms that form a rail channel, the clamping device including a pivot jaw assembly with jaw rail flange portions coupled to sides of the body portion. The pivot jaw is hingedly operated between an open and closed position. The rail arms further include a strap channel configured to hold a strap disposed around the side rail, and to secure the strap to the rail using a clamp bar via force exerted on rail and jaw flange portions of the clamp assembly, to effectively clamp the strap to the table.

Abstract: Disclosed are systems and methods for assisting with procedures involving a subject's joint, such as a joint. Robotic devices move and position the subject to manipulate the joint and sensing devices sense the joint gap. The robotic devices are controlled based on the joint gap. Novel techniques are disclosed for joint gap segmentation, approximating an uncertainty in determination of the varying dimension of the joint gap, and real-time motion analysis of the joint gap size. In some examples, a kinematic model of the patient's anatomy is utilized to provide robotically assisted manipulation of the same using the techniques described herein.

Abstract: In one implementation, a casket lowering system is configured to enable the lowering of a casket into a grave and includes: a casket support system configured to support the casket and temporarily suspend the casket above the grave; an electrically-actuated brake assembly coupled to the casket support system and configured to control the rate of descent of the casket support system into the grave; and a rechargeable power source electrically coupled to the electrically-actuated brake assembly and configured to provide electrical energy to the electrically-actuated brake assembly.

Abstract: Embodiments of a wheelchair and suspension system are provided. In one embodiment, a wheelchair or other vehicle having a wheel assembly is provided. The assembly includes, for example, a housing, a resilient member between two sleeves or casings, and a wheel support connected to a wheel. The resilient member compresses when there is an impact on the wheel and decompresses after the impact. In another embodiment, a wheelchair or other vehicle having a multi-purpose suspension system is provided. In one instance, the system provides suspension between to the main drive wheels and the frame. In a second instance, the system provides suspension between the anti-tip wheels and the frame.

Abstract: A charging system for a medical facility includes a patient support apparatus that has a base frame, an upper frame, a wheel to engage a floor surface, and a controller. A rechargeable battery is operably coupled to the base frame. The controller is configured to communicate with the rechargeable battery. A transmitting assembly is coupled to at least one of a wall surface and the floor surface of said medical facility. A receiving assembly is operably coupled to the base frame adjacent to the wheel. The receiving assembly is in communication with the rechargeable battery. The receiving assembly and the transmitting assembly selectively communicate to charge the rechargeable battery. An alert feature is in communication with the controller of the patient support apparatus. The alert feature is configured to emit an alarm when the controller indicates the rechargeable battery is at or below a predetermined charge level.

Abstract: A patient transport apparatus transports a patient over a floor surface. The patient transport apparatus includes a support structure and a drive wheel assembly having at least one drive wheel, a powered drive system coupled to the at least one drive wheel, and at least two user input devices. The apparatus also includes a controller coupled to the powered drive system and user input devices configured to determine which one of the user input devices is active and operable to cause the powered drive system to rotate the drive wheel and to maintain the other user input device as inactive, or passive.

Abstract: A massage device includes a shell defining a moving space therein, a driving member and a massage member. A lateral wall of the shell defines an opening to intercommunicate the moving space inside the shell with an outside environment out of the shell. The lateral wall extends along an insertion direction of the shell, and the moving space extends through a first exterior side of the lateral wall to the outside environment. The driving member is arranged in a chamber of the shell defined by an interior surface of the shell and the moving space is defined by a surface of the shell that is exterior to the interior surface of the chamber. The massage member is connected to the driving member in a transmission way and has a free end being swingable in a lateral direction of the shell under the driving of the driving member.

Abstract: A percussive therapy device that includes a housing, an electrical source, a motor positioned in the housing, a switch for activating the motor, a push rod assembly operatively connected to the motor and configured to provide reciprocating motion in response to activation of the motor, and a massage attachment secured to a distal end of the push rod assembly. The reciprocating motion of the push rod assembly has a user-adjustable amplitude.

Abstract: An assisting torque setting apparatus and method, wherein the apparatus is configured to generate a reference gait model by applying body information of a user to a predetermined body model, and set an optimal assisting torque by adjusting an assisting torque provided from a walking assistance apparatus to the user based on the reference gait model is disclosed.

Abstract: A spa is provided including a frame, a shell mounted to the frame defining a basin for holding water, at least one sensor for monitoring a spa component or water condition, a communications interface including a cellular transceiver, and a battery for providing power to the at least one sensor and to the communications interface when the spa is not connected to a power source. The spa also includes a controller in electrical communication with the at least one sensor and the communications interface. The controller is configured to, while the spa is not connected to the power source, receive information from the at least one sensor, process the received information, and cause the communications interface to wirelessly transmit the processed information to a remote source or central server.

Abstract: A suction assembly is described. The suction assembly includes a therapy unit with a body that can apply a supplemental therapy to a skin surface. The suction assembly also includes a cup that can be removably connected to the therapy unit and that can interface with a skin surface to define a chamber within the cup. A pump of the therapy unit can reduce a pressure within the chamber to draw the skin surface into the chamber in a cupping therapy. In response to the skin surface being drawn into the chamber, the body can move in a longitudinal direction to maintain contact with the skin surface. A wall of the cup is translucent and the suction assembly is dimensioned to provide a user with a view into the chamber through the wall of the cup that is substantially unobstructed by the housing.

Abstract: Containers for the storage of red blood cell compositions are disclosed. The container walls are made of a plastic composition that includes a polymeric material and at least one extractable agent that includes a terephthalate ester in an amount effective to suppress hemolysis in red blood cells.

Abstract: A feeding device includes a fluid reservoir and a nipple configured to be attached to the fluid reservoir. The nipple includes a body portion defining a compartment configured to contain a liquid so as to mimic a feel of a mother's breast. The body portion comprises a nipple tip comprising a fluid outlet. The nipple includes a base member attached to the body portion, the base member including an attachment portion configured to attach the nipple to the fluid reservoir. The base member comprises a fluid inlet in fluid communication with the fluid reservoir. The nipple includes a fluid passageway extending through the compartment from the fluid inlet to the nipple tip, where the fluid passageway allows fluid to flow from the fluid reservoir to the fluid outlet. A valve member positioned on the base member adjusts a flow rate of fluid from the fluid reservoir into the fluid passageway.

Abstract: Various aspects of the subject disclosure relate to a compounder system having a cartridge that includes fluid pathways controllable by valves of the cartridge. A pump component within the cartridge is actuable to move fluid through the controllable fluid pathways. The cartridge includes a needle extending from a cartridge body and fluidly coupled to at least one of the controllable fluid pathways. A vial puck is provided for attachment to a vial to be fluidly coupled to the cartridge by the needle. The vial puck may include a hygroscopic member to absorb fluid from the needle to ensure a dry disconnect. A shuttle valve may also be provided.

Abstract: An internal substance supplier includes a conveying mechanism including a conveying member configured to capture and convey an internal substance, and a supply mechanism including a scraping member disposed to cross a conveyance route of the substance by the conveying member in the conveying mechanism and configured to collide with the substance conveyed by the conveying member, a gliding member including a recessed groove configured to guide the substance colliding with the scraping member and scraped from the conveying member, to be adjacent to a position vertically above a die bore in a table in a compression-molding machine, and a push transfer member including a projection configured to come into contact with the substance, push the substance to a start edge of the recessed groove in the gliding member, and move along the recessed groove to transfer the substance to an end edge of the recessed groove.

Abstract: An internal element (310) for a feeding bottle (100) is provided, the feeding bottle comprising a teat component (110), and a container component (120), which together define a bottle volume extending longitudinally between a base end of the container component, and a top end of the teat component. The internal element (310) comprises a disc element (620) configured to be positioned within the bottle volume extending transverse the longitudinal axis, and further comprises one or more tab elements (640) protruding from an outer periphery (630) of the disc element for being received between interfacing parts of a coupling arrangement (340, 342) of the bottle.

Abstract: A therapeutic composition and a method of producing it by light-activating hypericin in a carrier or solvent. Preferably, the composition is made by combining dried flowers and/or flower stems of St. John's Wort with edible oil and exposing the mixture to the sun for a prolonged time. This process serves to light-activate the hypericin before its use and reduce risk of skin phototoxicity. The composition can be used for treating undesirable conditions such as mouth sores and vaginal infections.

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

Abstract: The invention is directed to methods and compositions of stabilizing phenylephrine formations. The composition has good time-dependent stability at low temperature and has no change in its outward appearance even after having been stored at least 6 months.

Abstract: Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Abstract: The present invention provides a novel method of initiating or escalating dofetilide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiographic monitoring from three days to one day.

Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a patient in order to increase the amount of ketones metabolized by mitochondria. Exemplary patients include those with Alzheimer's disease and insulin resistance.

Abstract: A formulation and a method for treating, preventing or ameliorating or alleviating in a patient the symptoms of hangover, or veisalgia, associated with a bout of excessive alcohol consumption are disclosed. More specifically, a formulation comprising L-cysteine, thiamine and pyridoxine and a method for treating, preventing, ameliorating, or alleviating in a patient one or more of the symptoms of nausea, headache, diminished concentration, malaise and/or tiredness, and a desire to consume greasy and/or fatty and/or oily foods, associated with a bout of excessive alcohol consumption are disclosed.

Abstract: Composition for use in the prevention and/or treatment of a mitochondrial dysfunction-related neurodegenerative diseases, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Abstract: Compositions contain citrulline and leucine or a metabolite thereof, such as hydroxyisocaproic acid (HICA) or beta-hydroxy-beta-methylbutyrate (HMB), including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for treatment of pre-diabetes, metabolic syndrome, or diabetes.

Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: Provided are methods of treating various forms of hearing loss caused by aberrant calcium fluxes in auditory cells. The methods encompass the administration of agents which prevent abnormal calcium fluxes, stabilize SERCA2b activity, or prevent ER UPR apoptotic responses. The methods include therapeutic treatments of subjects suffering from hearing loss as well as preventative treatments which protect auditory cells from cell death, for example as caused by exposure to loud noise.

Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).

Abstract: Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.

Abstract: Compositions of a stabilized chlorthalidone suspension and methods for making a stabilized chlorthalidone suspension include chlorthalidone along with a solubilizing and/or wetting agent, a suspending agent, and a viscosity increasing agent and/or an anti-caking agent, wherein the stabilized chlorthalidone suspension is a uniform dispersion with consistent concentration of chlorthalidone throughout the composition and storage.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

Abstract: An 5-(4,5-bis(4-chlorophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)pentanoic compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1P receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.

Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.

Abstract: Methods of treating a disease caused by a positive strand RNA virus. The methods include administering to a subject in need thereof an effective amount of a compound of Formula I or Formula II.

Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

Abstract: The present disclosure relates to a method of treating or preventing mitochondrial diseases by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.

Abstract: This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and/or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

Abstract: Compositions and methods of selectively activating Akt3 are provided.

Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

Abstract: A controlled release formulation comprising an opioid growth factor receptor (OGFR) antagonist and at least one pharmaceutically acceptable carrier has been developed, which is useful for treating cancer when locally administered at a disease site.

Abstract: Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an FGFR inhibitor (for example, AZD4547) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.